Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

被引:0
作者
Shuai Hao
Shuyi Xu
Liangzhu Li
Yaxian Li
Meiqi Zhao
Junsheng Chen
Shunying Zhu
Yueqing Xie
Hua Jiang
Jianwei Zhu
Mingyuan Wu
机构
[1] Shanghai Jiao Tong University,Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy
[2] Shanghai Jiao Tong University,Institute of Translational Medicine
[3] Jecho Laboratories,undefined
[4] Inc,undefined
来源
BMC Cancer | / 22卷
关键词
PD-L1; CXCR4; Antibody; Bispecific nanobody; Immunotherapy; Pancreatic cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 64 条
[1]  
Li C(2014)Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo Biotechnol J 9 652-63
[2]  
Li C(2020)RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis Front Oncol 10 1730-81
[3]  
Xiang XS(2022)Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer Biochim Biophys Acta Rev Cancer 1877 188676-3
[4]  
Sarantis P(2020)Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy World J Gastrointest Oncol 12 173-705
[5]  
Biankin AV(2015)Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy Subtyping Pancreat Cancer Cancer Cell 28 411-6
[6]  
Maitra A(2018)Targeting Treg cells in cancer immunotherapy Expert Rev Vaccines 17 697-513
[7]  
Collins JM(2019)Integrating oncolytic viruses in combination cancer immunotherapy Eur J Immunol 49 1140-42
[8]  
Redman JM(2018)FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy Nat Rev Immunol 18 498-86
[9]  
Gulley JL(2016)Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Oncologist 21 634-65
[10]  
Tanaka A(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer Lancet Oncol 13 879-33